Microdosing Amanita muscaria for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Microdosing Amanita muscaria for Health & Longevity

Created on 08/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

The mushroom's chemistry is well described: one compound calms nerve activity, another stimulates it, and drying or heating shifts the balance. No controlled human study of small repeated doses exists. Reported gains in sleep, mood and pain rest on user surveys; harms come from emergency admissions, undisclosed ingredients and measurable cadmium and lead. Confidence in claimed benefits is low. (Full Review)

Protocol

Typical dose range
0.2–2 g dried daily
Roughly 0.02–0.4 mg muscimol against measured content of 0.01–0.02% of dried weight, versus a reported psychoactive threshold near 6 mg
Best time of day
Morning or evening
Timing is reported to determine direction: 1–2 hours before bed for sleep, on waking for alertness. No mechanism supports the reversal
Half-life and dosing frequency
Once daily, single dose
Reported practice is a single daily dose rather than divided doses; no meaningful accumulation of parent compound between doses
Time to effect
Sleep, mood and pain
2–4 weeks
Window over which protocols describe assessment of the cumulative claims. No controlled timeline exists
Published single case
3.5 months
Interval over which the one published case reported meaningful change on a declining dose
Relaxation or alertness
30 minutes – 2 hours
Reported onset of the claimed acute effects after a dose

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Any seizure within the preceding 12 months, or a diagnosed epilepsy syndrome
  • History of psychotic disorder or bipolar I disorder
  • Chronic kidney disease with estimated glomerular filtration rate below 60 mL/min/1.73 m²
  • Hepatic impairment at Child-Pugh Class B or C
  • Blood lead at or above 5 µg/dL, or whole-blood cadmium at or above 5 µg/L, at baseline
  • Current benzodiazepine, opioid or alcohol use disorder, or ongoing prescribed therapy with any of those classes
  • Untreated moderate-to-severe obstructive sleep apnoea (apnoea-hypopnoea index above 15 events per hour)
  • Occupational drivers, pilots, and operators of heavy machinery
  • Anyone within 48 hours of planned general anaesthesia or procedural sedation
    •
Key Interactions
  • Alcohol, particularly alcohol-extracted tinctures
  • Z-drugs (zolpidem, zopiclone, eszopiclone)
  • Gabapentinoids (gabapentin, pregabalin)
  • Sedating antihistamines (diphenhydramine, doxylamine) and motion-sickness agents (dimenhydrinate, scopolamine)
  • Anticholinergic agents (atropine, glycopyrrolate) and cholinesterase inhibitors (pyridostigmine, donepezil)
  • Dopamine antagonists (haloperidol, risperidone, metoclopramide, domperidone)
  • Drugs that lower seizure threshold (bupropion, tramadol, ciprofloxacin)
  • Sedating supplements (valerian, kava, passionflower, ashwagandha, melatonin, magnesium glycinate, glycine, L-Theanine, cannabidiol)
  • Iron, zinc and calcium supplementation
  • Cannabis
  • Sauna and heat exposure
    •

Risk & Side Effects

  • High: Gastrointestinal and cholinergic reactions; sedation, drowsiness and psychomotor impairment; undisclosed adulterants and inaccurate labelling in commercial products
  • Medium: Acute intoxication and central nervous system depression with dose escalation; seizures and neuroexcitation; cadmium and lead exposure from chronic use
  • Low: Withdrawal-type symptoms after stopping; prolactin elevation and endocrine effects
  • Speculative: Cumulative excitotoxic neuronal injury from ibotenic acid; tolerance and physiological dependence; pro-inflammatory microglial priming

Monitoring

Marker Target Why
ALT and AST 10–26 U/L (men); 9–22 U/L (women) Detects hepatic stress from repeated exposure to unstandardised fungal material and from alcohol-based tinctures
Creatinine and eGFR eGFR above 90 mL/min/1.73 m² Both active compounds are cleared renally; reduced filtration prolongs exposure and impairs handling of a cadmium load
Whole-blood cadmium Below 0.5 µg/L This species concentrates cadmium from soil, and dried preparations carry the highest levels
Blood lead Below 1 µg/dL Lead is concentrated by the same soil-uptake mechanism and was highest of seven preparation methods in alcohol tinctures made from raw caps
Prolactin Men 3–13 ng/mL; non-pregnant women 3–20 ng/mL Oral muscimol raises prolactin dose-dependently, so a rise is the only available signal that a dose is systemically active rather than inert
CBC with differential Within reference; eosinophils below 3% Screens for hypersensitivity reactions to fungal material and for marrow effects of chronic metal exposure

Cadence: Liver enzymes and prolactin at 4 weeks; full panel including both metals at 3 months; every 6 months thereafter for as long as any regimen continues

Qualitative Assessment

  • Sleep onset latency and number of night wakings, ideally from a wearable rather than from recall
  • Morning alertness within the first hour of waking, and any next-day grogginess
  • Perceived stress and mood stability, scored on a fixed scale at the same time each day
  • Pain intensity and interference, where pain was the reason for starting
  • Cognitive clarity and working-memory performance during the 2–8 hour window after dosing
  • Any cholinergic signal — sweating, salivation, watery eyes, gut cramping — which indicates the dose is not sub-threshold
  • Any perceptual change whatever, which by definition means the dose has exceeded the microdose range
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.